Olezarsen 80 mg,
does it really help with Reduced fasting triglycerides at six months in familial chylomicronemia syndrome?
research showsThe grade is C. In the 66-person BALANCE trial, the placebo-adjusted six-month fasting triglyceride change with 80 mg was -43.5 percentage points, 95% CI -69.1 to -17.9, P<.001. The primary endpoint was a laboratory surrogate and the only confirmatory trial was small and funded solely by Ionis. Eleven versus one pancreatitis episodes are an important secondary signal, but hierarchical testing stopped after the 50-mg comparison failed. This gives C with 50 points.
ads claimCalling this a 43.5% triglyceride reduction obscures the scale. It was a -43.5-point placebo-adjusted difference in percent change, and pancreatitis was an exploratory secondary result after hierarchical testing stopped.
Useful facts when choosing a product
- Olezarsen is an antisense oligonucleotide targeting hepatic APOC3 mRNA.
- Drug and matching placebo were treatment materials; triglyceride testing and event adjudication were assessment procedures.
- The 60% power assumption was not a validated minimum important difference.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.olezarsen.UNK.fasting-triglycerides-at-in-familial-chylomicronemia-syndrome.reduce.placeboUnknown > Olezarsen > Unknown > fasting triglycerides at in familial chylomicronemia syndrome > Reduction claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
At 29 sites in 11 countries, 66 participants were randomized to 80 mg, 22; 50 mg, 21; or placebo, 23. All received at least one dose and entered the prespecified full analysis set. In the 45-person 80-mg versus placebo comparison, six-month values were missing for three versus one participant and were handled with prespecified jump-to-reference multiple imputation. Randomization used interactive response technology. Ionis fully funded the trial and employed five authors; company staff and a contractor also assisted with data, editing, and graphics. Olezarsen and matching placebo were trial materials; no separate company-supplied assessment tool was reported. The avoidable limitation was a total sample below 200.
Why this is classified as C (50)
A large triglyceride reduction was shown, but one 66-person manufacturer-only surrogate trial gives C with 50 points.
Counterpoint. C does not deny triglyceride lowering. It means that clinical-event benefit has not been independently replicated under multiplicity control.
Rejudgment record. Cross-check applied — Uses only the prespecified 80-mg triglyceride primary comparison as confirmatory evidence and separates the post-hierarchy pancreatitis result from the small manufacturer-only design
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced fasting triglycerides at six months | C | The 80-mg comparison was positive at -43.5 points but remained a surrogate. |
| Reduced acute pancreatitis | C | The event difference was large but was a nominal secondary result after hierarchical testing stopped. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Stroes ESG et al. 2024 BALANCE | Three-arm double-blind placebo-controlled phase 3 trial at 29 sites in 11 countries | 66 randomized and analyzed in the FAS, 22 at 80 mg, 21 at 50 mg, and 23 placebo; 45 in the 80-mg primary comparison | Fully funded by Ionis Pharmaceuticals, with company-employed authors and manuscript and data support | Mean percent change in fasting triglycerides from baseline to six months | 80 mg versus placebo -43.5 percentage points, 95% CI -69.1 to -17.9, P=.0009; 50 mg -22.4 points, -47.2 to 2.5, P=.08 | Confirmatory surrogate primary result; clinical-event secondary result exploratory |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Final verification and publication gate: Codex · Evidence date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Olezarsen 80 mg x triglyceride reduction in familial chylomicronemia syndrome — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/olezarsen-80mg-familial-chylomicronemia-fasting-triglycerides/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.